TMEM74B

Summary

TMEM74B (transmembrane protein 74B, HGNC:15893) is a protein-coding gene on chromosome 20p13, encoding Transmembrane protein 74B (Q9NUR3).

Predicted to be located in membrane.

Source: NCBI Gene 55321 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 34 total
• MANE Select transcript: NM_001304748

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15893
Approved symbol	TMEM74B
Name	transmembrane protein 74B
Location	20p13
Locus type	gene with protein product
Status	Approved
Aliases	FLJ11190
Ensembl gene	ENSG00000125895
Ensembl biotype	protein_coding
Entrez	55321

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 11 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000381894, ENST00000429036, ENST00000481747, ENST00000866484, ENST00000866486, ENST00000866487, ENST00000935819, ENST00000935820, ENST00000964217, ENST00000964218, ENST00000964219, ENST00000964220

RefSeq mRNA: 9 — MANE Select: NM_001304748 NM_001304748, NM_001304749, NM_001387329, NM_001387330, NM_001387331, NM_001387332, NM_001387333, NM_001387334, NM_018354

CCDS: CCDS13011

Canonical transcript exons

ENST00000429036 — 3 exons

Exon	Start	End
ENSE00001632223	1184302	1184981
ENSE00001683435	1180570	1181587
ENSE00001762213	1183771	1183948

Expression profiles

Bgee: expression breadth ubiquitous, 184 present calls, max score 91.30.

FANTOM5 (CAGE): breadth broad, TPM avg 0.4468 / max 27.0833, expressed in 237 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
185998	0.4468	237

Top tissues by expression

279 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	91.30	gold quality
right lung	UBERON:0002167	90.69	gold quality
nucleus accumbens	UBERON:0001882	88.43	gold quality
right frontal lobe	UBERON:0002810	86.52	gold quality
putamen	UBERON:0001874	85.47	gold quality
caudate nucleus	UBERON:0001873	85.24	gold quality
upper lobe of left lung	UBERON:0008952	85.17	gold quality
ileal mucosa	UBERON:0000331	85.08	silver quality
seminal vesicle	UBERON:0000998	84.88	gold quality
apex of heart	UBERON:0002098	84.61	gold quality
anterior cingulate cortex	UBERON:0009835	83.71	gold quality
cingulate cortex	UBERON:0003027	83.65	gold quality
upper lobe of lung	UBERON:0008948	83.47	gold quality
small intestine Peyer’s patch	UBERON:0003454	83.39	gold quality
Brodmann (1909) area 9	UBERON:0013540	83.15	gold quality
cortical plate	UBERON:0005343	82.84	gold quality
hypothalamus	UBERON:0001898	82.35	gold quality
small intestine	UBERON:0002108	82.25	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	81.72	gold quality
amygdala	UBERON:0001876	80.74	gold quality
right atrium auricular region	UBERON:0006631	80.52	gold quality
neocortex	UBERON:0001950	79.65	gold quality
skin of leg	UBERON:0001511	79.56	gold quality
telencephalon	UBERON:0001893	79.54	gold quality
cardiac atrium	UBERON:0002081	79.50	gold quality
forebrain	UBERON:0001890	79.46	gold quality
mucosa of transverse colon	UBERON:0004991	79.39	gold quality
frontal cortex	UBERON:0001870	79.13	gold quality
adenohypophysis	UBERON:0002196	78.80	gold quality
placenta	UBERON:0001987	78.79	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.71
E-MTAB-8060	no	41.89

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

27 targeting TMEM74B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-187-5P	99.74	70.26	1404
HSA-MIR-4524B-5P	99.57	71.68	1195
HSA-MIR-4524A-5P	99.57	71.73	1193
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-5690	99.25	67.58	1012
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-6829-5P	98.86	65.12	1480
HSA-MIR-374B-3P	98.63	68.24	1360
HSA-MIR-4691-5P	98.41	66.77	1343
HSA-MIR-6792-3P	98.41	66.86	1359
HSA-MIR-3670	97.88	64.39	763
HSA-MIR-503-5P	97.87	66.83	575
HSA-MIR-6787-3P	97.75	66.17	1233
HSA-MIR-4633-3P	93.85	63.56	534
HSA-MIR-6500-5P	93.85	63.64	522
HSA-MIR-1537-3P	90.51	63.57	105

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem74b	ENSDARG00000078868
mus_musculus	Tmem74b	ENSMUSG00000044364
rattus_norvegicus	Tmem74b	ENSRNOG00000081966

Paralogs (1): TMEM74 (ENSG00000164841)

Protein

Protein identifiers

Transmembrane protein 74B — Q9NUR3 (reviewed: Q9NUR3)

All UniProt accessions (2): Q9NUR3, Q5QPM3

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Similarity. Belongs to the TMEM74 family.

RefSeq proteins (9): NP_001291677, NP_001291678, NP_001374258, NP_001374259, NP_001374260, NP_001374261, NP_001374262, NP_001374263, NP_060824 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029695	TMEM74-like	Family

Pfam: PF14927

UniProt features (7 total): transmembrane region 2, compositionally biased region 2, chain 1, region of interest 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NUR3-F1	56.66	0.05

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 60 (showing top): TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, ROZANOV_MMP14_TARGETS_UP, AACTTT_UNKNOWN, VANTVEER_BREAST_CANCER_POOR_PROGNOSIS, STAT5A_01, HATADA_METHYLATED_IN_LUNG_CANCER_UP, NOTCH_DN.V1_UP, FOXN3_TARGET_GENES, ZNF362_TARGET_GENES, ZNF391_TARGET_GENES, ZNF410_TARGET_GENES, MIR15A_5P, MIR195_5P, MIR15B_5P, MIR16_5P

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	1

Protein interactions and networks

STRING

244 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM74B	TTC36	A6NLP5	433
TMEM74B	SS18L2	Q9UHA2	419
TMEM74B	RERGL	Q9H628	411
TMEM74B	ZNF665	Q9H7R5	393
TMEM74B	TMEM169	Q96HH4	391
TMEM74B	TMEM106C	Q9BVX2	365
TMEM74B	CPXM2	Q8N436	358
TMEM74B	NHSL1	Q5SYE7	348
TMEM74B	CDR2L	Q86X02	346
TMEM74B	PRSS53	Q2L4Q9	323
TMEM74B	KRT73	Q86Y46	322
TMEM74B	NUDT18	Q6ZVK8	322
TMEM74B	ENTREP1	Q15884	321
TMEM74B	LRRC45	Q96CN5	313
TMEM74B	RELL1	Q8IUW5	311

IntAct

2 interactions, top by confidence:

A	B	Type	Score
ABL1	TMEM74B	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (2): TMEM74B (Affinity Capture-RNA), TMEM74B (Co-fractionation)

ESM2 similar proteins: A0A1B0GU29, A6NLX4, A6QNY1, A9CBA0, B7ZWI3, O14669, O88472, P14784, P16297, P25918, P26896, Q0VFL4, Q13651, Q32M26, Q38J84, Q38J85, Q3SYS8, Q58CT8, Q5BK39, Q5EAA5, Q5HZE8, Q5NCP0, Q5RCL0, Q64322, Q68DV7, Q6AXS2, Q6AXU5, Q6NUJ2, Q6UWV7, Q86UW2, Q8BHB3, Q8BLR5, Q8BSU2, Q8C353, Q8C708, Q8K1T1, Q8MII8, Q8N6P7, Q8NET5, Q8R182

Diamond homologs: Q8BQU7, Q96NL1, Q9NUR3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

34 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	34
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

412 predictions. Top by Δscore:

Variant	Effect	Δscore
20:1181585:CAG:C	acceptor_gain	0.9900
20:1181587:GCTG:G	acceptor_loss	0.9900
20:1181588:C:CC	acceptor_gain	0.9900
20:1181588:CT:C	acceptor_loss	0.9900
20:1181583:GGCAG:G	acceptor_gain	0.9800
20:1181584:GCAG:G	acceptor_gain	0.9800
20:1181585:CAGC:C	acceptor_gain	0.9800
20:1181586:AG:A	acceptor_gain	0.9800
20:1183781:ATACC:A	donor_gain	0.9700
20:1181584:GCAGC:G	acceptor_gain	0.9400
20:1181587:GCT:G	acceptor_gain	0.9400
20:1183783:ACC:A	donor_gain	0.9400
20:1183784:CCC:C	donor_gain	0.9400
20:1183955:A:T	acceptor_gain	0.9400
20:1181229:C:CT	acceptor_gain	0.9300
20:1181586:A:T	acceptor_gain	0.9300
20:1181586:AGCTG:A	acceptor_gain	0.9300
20:1181585:CAGCT:C	acceptor_gain	0.9200
20:1181588:C:A	acceptor_gain	0.9100
20:1181589:T:G	acceptor_gain	0.9100
20:1183781:ATAC:A	donor_gain	0.9100
20:1184120:AGCT:A	donor_gain	0.9000
20:1184121:G:C	donor_gain	0.8900
20:1184177:C:CA	donor_gain	0.8800
20:1184455:A:AC	donor_gain	0.8600
20:1184456:C:CC	donor_gain	0.8600
20:1181230:A:T	acceptor_gain	0.8500
20:1183805:TC:T	donor_gain	0.8500
20:1183806:CC:C	donor_gain	0.8500
20:1183817:C:A	donor_gain	0.8500

AlphaMissense

961 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:1181223:A:C	S132R	0.997
20:1181223:A:T	S132R	0.997
20:1181225:T:G	S132R	0.997
20:1181221:C:T	G133E	0.996
20:1181222:C:A	G133W	0.994
20:1181222:C:G	G133R	0.994
20:1181222:C:T	G133R	0.994
20:1181200:G:T	A140E	0.988
20:1181242:G:T	A126D	0.988
20:1181212:A:C	L136R	0.985
20:1181221:C:A	G133V	0.985
20:1181186:G:T	R145S	0.979
20:1181209:A:T	V137E	0.979
20:1181230:A:T	L130Q	0.979
20:1181201:C:G	A140P	0.978
20:1181230:A:C	L130R	0.977
20:1181212:A:T	L136Q	0.976
20:1181250:A:C	F123L	0.974
20:1181250:A:T	F123L	0.974
20:1181252:A:G	F123L	0.974
20:1181191:A:G	I143T	0.972
20:1181236:A:T	V128D	0.971
20:1181191:A:T	I143N	0.970
20:1181188:G:A	P144L	0.969
20:1181230:A:G	L130P	0.968
20:1181198:A:C	Y141D	0.966
20:1181212:A:G	L136P	0.965
20:1181239:A:T	L127H	0.963
20:1181191:A:C	I143S	0.958
20:1181189:G:T	P144T	0.957

dbSNP variants (sampled 300 via entrez): RS1000172295 (20:1183347 A>G), RS1000284108 (20:1188939 C>A), RS1000466601 (20:1188550 A>G), RS1000718899 (20:1184967 C>T), RS1000722824 (20:1186369 G>A), RS1000968334 (20:1190497 T>C), RS1001021928 (20:1190350 C>A,T), RS1001724552 (20:1185745 C>A,G), RS1001732126 (20:1190025 T>C), RS1002174481 (20:1185679 G>A), RS1002393588 (20:1185935 A>G), RS1002509753 (20:1186997 G>A,T), RS1002727380 (20:1187104 G>A), RS1003033575 (20:1182033 C>T), RS1003735840 (20:1188478 C>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST000269_7	Multiple sclerosis	8.000000e-07
GCST007682_3	Thyroxine levels	8.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	3
Resveratrol	affects cotreatment, decreases expression	2
Oxygen	decreases reaction, increases expression	2
Cyclosporine	decreases expression	2
aristolochic acid I	decreases expression	1
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine	decreases reaction, increases expression	1
OTX015	decreases expression	1
bisphenol F	increases methylation	1
mivebresib	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
entinostat	increases expression	1
K 7174	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	increases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	decreases methylation	1
Cisplatin	affects cotreatment, increases expression	1
Copper	affects cotreatment, decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Silicon Dioxide	decreases expression	1
Thimerosal	decreases expression	1
Urethane	decreases expression	1
Aflatoxin B1	decreases methylation	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.